Nurix Therapeutics (NRIX) Accounts Payables (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Accounts Payables data on file, last reported at $12.2 million in Q2 2026.

• On a quarterly basis, Accounts Payables rose 105.04% year-over-year to $12.2 million in Q2 2026; TTM through May 2026 was $12.2 million, a 105.04% increase from a year earlier, with the FY2025 full-year figure at $11.2 million, down 2.33% from the prior year.
• Accounts Payables for Q2 2026 stood at $12.2 million, up from $10.3 million in the prior quarter.
• Over the last five years, Accounts Payables for NRIX reached as high as $12.2 million in Q2 2026 and fell as low as $2.2 million in Q3 2023.
• Historically, Accounts Payables has averaged $6.8 million across 5 years, with a median of $6.0 million in 2022.
• Across the five-year window, Accounts Payables sank 63.87% in 2023 and surged 119.73% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $5.1 million in 2022, then increased by 26.4% to $6.4 million in 2023, then surged by 79.38% to $11.5 million in 2024, then retreated by 2.33% to $11.2 million in 2025, then rose by 8.85% to $12.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $12.2 million in Q2 2026, $10.3 million in Q1 2026, and $11.2 million in Q4 2025.